What is the recommended dosing of MiraLAX (polyethylene glycol 3350) for pediatric patients with constipation, considering age and weight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MiraLAX (Polyethylene Glycol 3350) Pediatric Dosing

For pediatric constipation, start MiraLAX at 0.8 g/kg/day (approximately 1 capful or 17g per 20kg child) mixed in at least 4-8 ounces of liquid, adjusting the dose every 3 days to achieve 1-2 soft, painless stools daily. 1

Initial Dosing by Age and Weight

Standard Maintenance Dosing

  • Starting dose: 0.8-1.0 g/kg/day for all pediatric ages 1, 2
  • Effective maintenance dose: Typically 0.78-0.84 g/kg/day based on clinical response 3, 4, 2
  • Dose range: 0.27-1.42 g/kg/day depending on individual response 2

Age-Specific Considerations

  • Infants <18 months: Mean effective dose 0.78 g/kg/day (range 0.26-1.26 g/kg/day) 4
  • Toddlers <2 years: Mean effective dose 0.8 g/kg/day, with short-term dosing at 1.1 g/kg/day and long-term at 0.8 g/kg/day 3
  • Children ≥2 years: Mean effective dose 0.84 g/kg/day (range 0.27-1.42 g/kg/day) 2

Administration Guidelines

Mixing Instructions

  • Mix powder in at least 4-8 ounces of liquid (water, juice, coffee, or tea) 1
  • Juices with sorbitol content (like prune or apple juice) provide synergistic osmotic effect 1
  • Insufficient liquid volume is the most common cause of treatment failure 1

Dose Titration

  • Adjust dose every 3 days to achieve 1-2 soft, painless stools daily 1, 2
  • Target stool consistency: Soft but formed (not watery) 2
  • If diarrhea occurs: Reduce dose immediately; this is the only common adverse effect 3, 4

Special Clinical Situations

Bowel Preparation (Pre-Procedure)

  • Dose: 1.5 g/kg/day for 4 days before procedure 1
  • Day 4: Clear liquid diet only 1
  • Alternative: 1-day preparations are effective but less studied 1

Dysfunctional Elimination with Constipation

  • Average effective dose: 0.63 g/kg/day 5
  • Expected outcomes: 85-91% resolution of constipation with improvement in voiding symptoms 5, 3

Critical Safety Checks Before Starting

Mandatory Pre-Treatment Assessment

  • Rule out bowel obstruction or paralytic ileus before initiating therapy 1
  • Check for fecal impaction: May require manual disimpaction or enema first 1
  • Ensure adequate baseline fluid intake: PEG requires water to work osmotically 1

When to Add Rectal Therapy

  • If no bowel movement after 3-4 days: Add bisacodyl suppository (10mg) or glycerin suppository while continuing PEG 1
  • For persistent constipation: Consider adding oral stimulant laxative (senna or bisacodyl) to PEG regimen 1

Expected Outcomes and Duration

Treatment Response

  • Stool frequency: Increases from ~2-3 stools/week to 15-17 stools/week 2
  • Time to response: Typically within first week of therapy 3, 2
  • Long-term efficacy: Response is durable over 6 months in adults, with similar efficacy expected in children 1

Maintenance Strategy

  • Continue dosing once bowel movements normalize rather than stopping abruptly 1
  • Mean treatment duration: 6-11 months in clinical studies 3, 4

Common Clinical Pitfalls to Avoid

Dosing Errors

  • Inadequate liquid volume reduces efficacy significantly 1
  • Not confirming adequate daily fluid intake beyond mixing liquid leads to treatment failure 1
  • Assuming treatment failure without first optimizing dose and ensuring compliance leads to premature discontinuation 1

Timing Errors

  • Delaying rectal intervention beyond 3-4 days increases risk of fecal impaction 1
  • Stopping therapy too early when symptoms improve rather than continuing maintenance 1

Adverse Effects

Common and Manageable

  • Diarrhea: Most common adverse effect (reported in 9-32% of patients), resolves with dose reduction 5, 3, 4
  • Abdominal distension, flatulence, nausea: Generally mild 1
  • No significant adverse effects requiring discontinuation in clinical studies 3, 4, 2

Adjunctive Measures

Lifestyle Modifications

  • Increase dietary fluids and fiber if adequate fluid intake is ensured 1
  • Establish regular toileting habits, especially after meals 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.